Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06412224
EARLY_PHASE1

The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR)

Sponsor: Li Xiaorong

View on ClinicalTrials.gov

Summary

This study aims to slow down disease progression, reduce postoperative complications and decrease retreatment frequency in subjects with proliferative diabetic retinopathy (PDR) by administering a single subretinal injection of RRG001 gene therapy after vitrectomy.

Official title: An Exploratory ITT(Investigator Initiated Study) Study to Evaluate the Preliminary Safety and Efficacy of Single Subretinal Injection of RRG001 at the End of or After Vitrectomy in Subjects With PDR

Key Details

Gender

All

Age Range

20 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

6

Start Date

2023-12-20

Completion Date

2028-12-31

Last Updated

2024-05-14

Healthy Volunteers

No

Interventions

DRUG

RRG001

Administered by subretinal injection. Dosage form: injection.

Locations (1)

Tianjin medical university eye hospital

Tianjin, China